PHASQ PhaseBio (PNK) falls to $0.000001 on 30 Jan 2026: top loser, delisting
PHASQ stock plunged during market hours to $0.000001 on 30 Jan 2026, a -99.0% one-day change from the prior close of $0.000100. Trading volume was light at 2,500 shares versus a 50-day average of 22,310, and the quote shows a market cap effectively at $0.00 on the PNK exchange in the United States. Investors are reacting to continued restructuring and potential delisting signals; this report explains price drivers, key ratios, and what Meyka AI’s model and grade indicate for holders and traders.
PHASQ stock: intraday price and trading dynamics
PhaseBio Pharmaceuticals, Inc. (PHASQ) traded at $0.000001 with both the day low and high at that price, reflecting negligible liquidity on the PNK exchange in the United States. Volume was 2,500, well below the average volume of 22,310, which magnified price moves and increased spread risk.
The stock’s 50-day average is $0.000236 and its 200-day average is $0.000666, highlighting a sustained collapse from the 12-month high of $0.03990. Sparse trading and delisting notices make short-term technical trading risky.
PHASQ stock: fundamentals and financial ratios
PhaseBio’s trailing EPS is -2.14, and reported metrics show operating cash flow per share TTM of -1.61 and free cash flow per share TTM of -1.70, underlining negative operating cash trends. The data shows a current ratio of 1.75 and cash per share TTM of 1.42, but shareholders’ equity per share is -3.16, indicating balance sheet impairment.
Price-based ratios are distorted: the trailing P/E is effectively negative and not meaningful for valuation. These fundamentals explain why valuation metrics are unreliable while the company remains in restructuring and limited trading.
PHASQ stock: catalysts, risks, and recent news
Recent commentary flagged the company as potentially delisted; MarketBeat lists the NASDAQ:PHAS monitoring report, which has pressured liquidity and investor confidence source. PhaseBio filed Chapter 11 reorganization previously, and that background continues to affect sentiment and listing status.
Key risk factors are low float, potential delisting, and clinical-stage dependency on lead candidates such as bentracimab (PB2452). Opportunities would require fresh financing, successful clinical or commercial developments, or a restructuring outcome that restores trading normalcy.
PHASQ stock: technical context and market positioning
Technically, PHASQ sits far below moving averages with a 50-day average of $0.000236 and a 200-day average of $0.000666, marking multi-month downward momentum. Relative volume is 0.11, signaling weak market interest and high slippage risk for any size order.
Sector peers in Healthcare and Biotechnology show much higher liquidity and market caps, so PHASQ’s microcap status on PNK puts it outside normal analyst coverage and index flows.
Meyka AI rates PHASQ with a score out of 100
Meyka AI rates PHASQ with a score out of 100: 58.96 (C+) — SUGGESTION: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects material downside risks from thin liquidity and restructuring, along with limited upside without a clear operational turnaround.
Meyka AI provides this grade as informational only; it is not financial advice. For more detail see our PHASQ stock page on Meyka: Meyka PHASQ page.
Final Thoughts
PHASQ stock moved to $0.000001 on 30 Jan 2026, a near-total collapse from its 12-month high of $0.03990. Trading volume of 2,500 shares and an average volume of 22,310 highlight extreme illiquidity that creates execution and valuation risk for holders. Fundamental signals — EPS -2.14, negative operating cash flow per share -1.61, and shareholders’ equity per share -3.16 — point to a company still operating under restructuring constraints. Meyka AI’s forecast model projects a 12-month median price of $0.000000 given current listing uncertainty and the absence of reliable recovery signals; this implies an effective downside to zero from the current quote. Forecasts are model-based projections and not guarantees. For traders, PHASQ represents a high-risk microcap with potential binary outcomes: recovery through restructuring and financing or further loss and possible delisting. We recommend close monitoring of official filings, liquidity, and any exchange notices before initiating positions. Meyka AI, as an AI-powered market analysis platform, will update this view if official events change the capital structure or listing status.
FAQs
Why did PHASQ stock drop so sharply today?
PHASQ stock fell due to extremely low liquidity, prior Chapter 11 restructuring history, and market notices about potential delisting. Thin volume amplified a move from the prior close of $0.000100 to $0.000001.
Is PHASQ stock likely to be delisted?
Market monitoring reports and the company’s restructuring history increase delisting risk. Delisting is not certain, but the exchange status and official filings should be watched closely for definitive signals.
What does Meyka AI forecast for PHASQ stock?
Meyka AI’s forecast model currently projects a 12-month median price of $0.000000 given present data and listing uncertainty. Forecasts are model-based projections and not guarantees.
Should I buy PHASQ stock at current levels?
Current conditions show extreme risk: near-zero price, poor liquidity, and restructuring background. Investors should avoid buying without clear evidence of financing or listing resolution and should seek professional advice.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
